Navigation Links
XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting

lf of 2007 and the ability of XTENT to enroll the anticipated number of patients in its CUSTOM III trial. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of our most recent quarterly report on Form 10-Q for the quarter ended March 31, 2007. This quarterly report was filed with the SEC on May 14, 2007, and is available on our investor relations website at www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Information about XTENT is available at our website at http://www.xtentinc.com.

CONTACT: Investor Relations, Tim Kahlenberg, Chief Financial Officer ofXTENT, Inc., +1-650-475-9400, ; or Media Relations,Aimee Corso, +1-310-780-2661, , for XTENT, Inc. tkahlenberg@xtentinc.com acorso@weisscommpartners.com

Web site: http://www.xtentinc.com/

Ticker Symbol: (NASDAQ-NMS:XTNT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

Post Your Comments:
(Date:11/25/2009)..., WESTON, Fla., Nov. 25 /PRNewswire-FirstCall/ -... ASFX) ("the Company") is pleased to announce that...ion management office in Shanghai, China. ,, AS...ding an essential gateway for the development and ... products for children and adults to be distribute...
(Date:11/25/2009)...RINCETON, N.J., Nov. 25 ...e pharmaceutical company committed to discovering,...at viral infections, reported financial results fo...tember 30, 2009 Pharmasset held $58.4 million in c... ,, Pipeline Update and 2009 Highlights ,,...
(Date:11/25/2009)...XTON, Pa., Nov. 25 BioTrends Resea...nds(TM) : Stelara report, the first in a mult...g the launch of Centocor Ortho-Biotech,s Stelara, ...f availability. Each wave of the report provides ...ists and qualitative information from a subset of ...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Iowa Drug Card a Huge Success With Iowans 55345 1Iowa Drug Card a Huge Success With Iowans 55345 2VA Chiefs Vow to The American Legion 3A We Will End Vet Homelessness 55343 1VA Chiefs Vow to The American Legion 3A We Will End Vet Homelessness 55343 2Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 1Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 2Mayo Clinic Proceedings 3A Common Blood Disorder May Not be Linked to as Many Serious Diseases as Previously Thought 55341 3
... out of ten patients taking,once-daily Lialda rema...TON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- ...nsion study (303),presented at the British Society...tland in March 2007 showed Shire plc,s,Lialda(mesa...atients. Today, secondary endpoints of study 303 w...
...tion in Risk of Hospitalization,from Crohn,s Disea... 22, 2007 /PRNewswire-FirstCall/ -- Abbott,today a...otal study,presented at the Digestive Disease Week...ts with moderate to severely active,Crohn,s diseas...therapy were almost 60 percent less likely than pa...
Other Medicine Technology:Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
(Date:11/27/2009)... Nov. 27 Preventing dis... fortunately every year, new vaccines are being ad...ccines boost immunity for the same period of time?...needed to keep immunity strong? ,, In this mo...ican Academy of Pediatrics, Michael Pichichero MD,...
(Date:11/27/2009)...-emission vehicles may reduce future disease burde...HealthDay News) -- Encouraging city dwellers to wa...uch greater public health benefits than increased ...ve found. , The study compared the projected he...nsport scenarios for London, England, and Delhi, I...
(Date:11/27/2009)...lti-purpose bilingual coloring books designed for ...iness community to educate - inform parents and ch...issues to Dinosuars to ABC,S and a host of other t...(PRWEB) November 27, 2009 -- Today’s childre... them busy any hour of the day, but one of the old...
(Date:11/26/2009)...., Nov. 27 The diabetes population...next 25 years and annual medical spending on the d...113 billion today, according to a study published ...ional Changing Diabetes ® Program (NCDP), a ... by a team from the University of Chicago. ,, A...
(Date:11/26/2009)...n on an emotional rollercoaster, study finds , ...l it the fear factor meets the jubilant sports fan...ecially those who root for the winning team -- enj...tested match and victory was in doubt, producing f...at this Thanksgiving weekend as you,re glued to th...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3
...eilman Center,electro-mechanical manufacturing pla... a 2007 IndustryWeek magazine "Best Plant Finalist...e on the leading edge of efforts to,increase compe...09/MEDRADLOGO ) MEDRAD,s Heilman Center plant wa...
... patients, side effects impacting cognition don,t ...ng to a new survey, the cognitive impairment exper...be long-lasting and severely affect their personal...nize or multi-task have led to significant problem...
...7 The first significant genetic finding in premen...rted. PMDD is a very severe form of the more comm... heritable, affects 5-8% of women, and is associat... that quality of life is seriously impacted. Prev...
...Sales of World,s First Pocket Ultrasound ...if., Oct. 2 Siemens Medical,Solutions (http://ww...of medicine,with today,s launch of the world,s sma...1.6 pounds, and fits easily,into a lab coat pocket...
...imax GmbH, Campbell,CA, is pleased to announce tha...nc. the company is moving to larger premises in No...d. As of October 1st, 2007,joimax, Inc. will be lo...Michael Stek, CEO of the joimax, Inc. "Due to the ...
... Phylonix Pharmaceuticals, Inc. today announced t...l Business Innovation Grant (SBIR) from the Nation...lth (NIH) to develop zebrafish eye disease models ...onserved organ and the basic structure between hum...
Other Medicine News:Health News:MEDRAD Plant Named IndustryWeek Magazine Award Finalist 2Health News:MEDRAD Plant Named IndustryWeek Magazine Award Finalist 3Health News:Cognitive deficits lead to 'loss of self' among cancer patients 2Health News:First significant genetic finding in severe PMS, or PMDD 2Health News:Good Imaging Now Comes in the World's Smallest Ultrasound Package 2Health News:Good Imaging Now Comes in the World's Smallest Ultrasound Package 3Health News:NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases 2
Rheumatoid Factor Control
Microalbumin Urine Control
...he K-ASSAY Liquid Lipid Control is intended for us...sample of known concentration for monitoring assay...K-ASSAY Liquid Lipid Control with patient serum sp...tuents. The user can compare observations with exp...
Lyophilized ITA Control for K - ASSAY® Reagents
Medicine Products: